TickerTain
TickerTain
NewsroomShortsPortfolioConvergence
NewsroomShortsPortfolioConvergence
$ANTHROPIC·$MA····$INTC····$BLUE-ORIGIN·$SPCX····$CRWV····$CRM····$MSFT····$NVDA····$ORCL····$CURSOR·$AAPL····$OPENAI·$AMZN····$UBER····$GOOGL····$META····$TSLA····$DATABRICKS·$PERPLEXITY·$LYFT····$NBIS····$TSM····$LITE····$ANDURIL·
$ANTHROPIC·$MA····$INTC····$BLUE-ORIGIN·$SPCX····$CRWV····$CRM····$MSFT····$NVDA····$ORCL····$CURSOR·$AAPL····$OPENAI·$AMZN····$UBER····$GOOGL····$META····$TSLA····$DATABRICKS·$PERPLEXITY·$LYFT····$NBIS····$TSM····$LITE····$ANDURIL·
←

david ricks

T3 · host / generalist

CEO since 2021, 29-year company veteran, former head of China operations, board member of Adobe, engineer/MBA background.

1 call·1 name·100% bull·last heard 2 years ago·In Good Company with Nicolai Tangen
track record

no scored calls yet — needs a stated position or a categorical verdict, with a matured window vs SPY

top calls

highest conviction · one per company
1sthigh conviction
$LLYEli Lilly

Lilly CEO: GLP-1 franchise targets 1B patients, R&D time halved, AI boosting manufacturing

Tirzepatide and pipeline GLP-1s address obesity as choice not affliction with downstream benefits on cardiovascular, kidney, liver disease (40% of healthcare costs) and addiction; R&D development time cut nearly in half via parallel processing and decision gates; AI optimizing manufacturing and chemistry.

In Good Company with Nicolai Tangen2025-02episode →

most discussed · click a bar to filter

  • $LLY

recurring themes

  • GLP-1 & Metabolic Drugs1
  • Life Sciences & Drug Development1
  • AI Drug Discovery1
  • Healthcare Systems & Policy1
  • AI in Healthcare1
1 total
$LLY
···
Eli Lilly
HIGHdavid ricks·In Good Company with Nicolai Tangen·2 years ago·David Ricks - CEO of Eli Lilly | Podcast | In Good Company | Norges Bank Investment Management
Lilly CEO: GLP-1 franchise targets 1B patients, R&D time halved, AI boosting manufacturing
Tirzepatide and pipeline GLP-1s address obesity as choice not affliction with downstream benefits on cardiovascular, kidney, liver disease (40% of healthcare costs) and addiction; R&D development time cut nearly in half via parallel processing and decision gates; AI optimizing manufacturing and chemistry.
"I think we can easily say that weight management will become more like a choice than an Affliction and that's good we can also say that we've learned in the last 15 months that ma…"
4:00
9
GLP-1 & Metabolic Drugstailwind
Lilly CEO: GLP-1 franchise targets 1B obesity patients with downstream disease benefits
Tirzepatide and next-gen GLP-1s can convert obesity from affliction to choice, with proven cardiovascular benefits and emerging data on kidney, liver, Alzheimer's, and addiction (smoking, alcohol, opioids) addressing 40% of developed-market healthcare costs.
8
Life Sciences & Drug Developmenttailwind
Lilly halves drug development time via parallel processing and decision-speed culture
Cut preclinical time from 4-5 years to 2.5, clinical from 10 to 5.9 years via parallel manufacturing and pre-specified decision gates; structural advantage if repeatable across pipeline.
8
AI Drug Discoverytailwind
Lilly CEO: AI accelerates micro-steps in drug discovery, not end-to-end molecule generation
AI currently used for predicting individual experiments, synthetic data enrichment, and chemistry suggestion via diffusion models - cutting preclinical time further; production optimization already yielded 8% efficiency gain worth hundreds of millions.
8
Healthcare Systems & Policymixed
China leapfrogs Europe in drug access speed, targeting first-launch status globally
China reduced drug lag from 7 years to under 12 months vs US with regulatory harmonization, while Europe's 2.5-year post-approval delay wastes patent life; China aims to be first launch market worldwide.
7
AI in Healthcaretailwind
Generative AI for chemistry exploration expands molecular search space beyond human intuition
Diffusion models suggest novel chemical starting points in 10^60 molecular space, augmenting chemist creativity; long-term potential to accelerate lead optimization but requires wet-lab validation.
7
Advanced Manufacturingtailwind
AI-driven production optimization unlocks 8% capacity gain for GLP-1 manufacturing
Small AI intervention in production bottleneck increased output 7-8%, worth hundreds of millions to billions in revenue; digital control of manufacturing enables faster changes vs physical reconfiguration.